Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
DCTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Delcath Systems, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Delcath Systems, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How DCTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-24 | Del-Liver | Phase 2 data presentation | Phase 2 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| HEPZATO KIT | |||
| CHEMOSAT |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepzato Kit (melphalan HDS) Small MoleculesMarketedNCT05022901 | Metastatic Ocular Melanoma | Approved | ACTIVE NOT_RECRUITING | 30 | Mar 1, 2024 | ||||||
| Hepzato Kit (melphalan HDS) Small MoleculesNCT06607458 | Refractory Metastatic Colorectal Cancer | Phase 2 | RECRUITING | 90 | Oct 1, 2027 | ||||||
| Hepzato Kit (melphalan HDS) Small MoleculesNCT06875128 | Metastatic Breast Cancer in the Liver | Phase 2 | RECRUITING | 90 | Aug 1, 2029 | ||||||
| Hepzato Kit (melphalan HDS) Small MoleculesMarketedNCT02678572 | Ocular Melanoma | Approved | COMPLETED | 102 | Aug 15, 2023 | ||||||
| Hepzato Kit (melphalan HDS) Small MoleculesMarketedNCT00324727 | Intraocular Melanoma | Approved | COMPLETED | 93 | Aug 1, 2012 |
Clinical Trial Results
Readouts, endpoints and source filings for every DCTH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| melphalan | liver-dominant metastatic uveal melanoma | 2026-10-19 | objective response rate: 66.7%; disease control rate: 75%; median hepatic progression free survival: 18.4 months; median overall survival: 28 monthsRead More | Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sylvester John RichardDirector | Grant/Award | 22,500 22,500 held | $0.00 | 05/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DCTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.3 % | 2.34 M | 185.67 K | -56.95% ( -245.58 K) |
Ownership Trends
DCTH Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How DCTH ranks across every disease it competes in
DCTH News
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems, Inc. announced its participation in two upcoming investor conferences. The UBS Global Healthcare Conference will take place on November 10, 2026, in Palm Beach Gardens, FL, followed by Canaccord Genuity's MedTech Forum on November 11, 2026, in New York, NY. This engagement highlights the company's focus on interventional oncology.
Read more →Delcath Systems to Host Third Quarter 2026 Earnings Call
Delcath Systems, Inc. will host a conference call on November 9, 2026, to discuss its third quarter results. The call is scheduled for 8:30 AM Eastern Time. The company specializes in interventional oncology, particularly for liver cancers, with products like HEPZATO KIT and CHEMOSAT. Both products are designed to deliver high-dose chemotherapy while minimizing systemic exposure.
Read more →Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath Systems, Inc. announced its clinical program presentations at the ESMO Congress 2026, highlighting the efficacy of percutaneous hepatic perfusion (PHP) in treating liver-dominant metastatic uveal melanoma. The independent analysis revealed a 66.7% objective response rate and 75% disease control rate. The presentations will include updates on ongoing trials for metastatic breast and colorectal cancers.
Read more →Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. has announced the granting of equity awards as inducements to four new employees starting in July and August 2026. These awards, approved by the Compensation Committee, are in the form of Restricted Stock Units (RSUs) totaling 34,000. This move reflects the company's commitment to enhancing its workforce in the interventional oncology sector.
Read more →Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
Delcath Systems, Inc. reported its financial results for the second quarter of 2026, showing a total revenue of $29.1 million, which is an increase from $24.2 million in the same quarter of 2025. The revenue from the HEPZATO KIT™ also saw a notable rise, reaching $27.1 million compared to $22.5 million in the previous year. This growth highlights the company's ongoing success in the interventional oncology market.
Read more →Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
Delcath Systems, Inc. will attend the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA. The company specializes in interventional oncology, particularly for liver cancers. This participation reflects their ongoing commitment to advancing treatment options in this field.
Read more →Delcath Systems to Host Second Quarter 2026 Earnings Call
Delcath Systems, an interventional oncology company, announced it will host an earnings call on August 6, 2026, to discuss its second quarter results. The call is scheduled for 8:30 AM Eastern Time. This event highlights the company's ongoing commitment to transparency and investor engagement.
Read more →Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Delcath Systems has commenced its Phase 2 clinical trial for HEPZATO, with the first patient dosed at the European Institute of Oncology in Milan. This trial aims to evaluate the drug in combination with standard care for liver-dominant metastatic breast cancer. The study, named DELUMA, represents a significant step in addressing this challenging condition.
Read more →Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
Delcath Systems has announced two abstracts related to investigator-initiated trials that will be presented at ASCO 2026. The details of these trials-in-progress are expected to provide insights into ongoing research efforts. This announcement highlights Delcath's commitment to advancing cancer treatment options.
Read more →Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Delcath Systems is set to participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference. This event provides a platform for the company to engage with investors and discuss its business strategies. Further details about the conference and Delcath's agenda were not disclosed.
Read more →Delcath Systems Reports First Quarter 2026 Results and Business Highlights
Delcath Systems reported a total revenue of $25.0 million for Q1 2026, marking an increase from $19.8 million in Q1 2025. HEPZATO KIT revenue also saw substantial growth, contributing $23.3 million. However, the company faced a net loss of $1.1 million, a reversal from the previous year's net income. The publication of the CHOPIN trial results is anticipated to positively influence future prescribing patterns.
Read more →Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Delcath Systems presented new data on percutaneous hepatic perfusion with melphalan (M-PHP) at the ESMO Breast Cancer Congress 2026. The retrospective analysis involved 15 patients with liver-dominant metastatic breast cancer, showing a 60% hepatic partial response rate. However, safety concerns were noted, with significant adverse events reported. The findings underscore the potential of M-PHP and the need for further studies.
Read more →Delcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems, Inc. will host its first quarter 2026 earnings call on May 7, 2026, at 8:30 AM ET. The call will discuss financial results for the quarter ending March 31, 2026. Delcath is known for its innovative interventional oncology products, including HEPZATO KIT and CHEMOSAT, which target liver cancers.
Read more →Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
Delcath Systems, Inc. has announced that its CHEMOSAT Hepatic Delivery System for Melphalan has been included as a recommended liver-directed regional therapy option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma. This recognition may enhance treatment options for patients suffering from this rare form of cancer. The inclusion underscores the system's potential effectiveness and credibility in clinical settings.
Read more →Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Delcath Systems, Inc. will participate in the Society of Interventional Radiology 2026 Annual Scientific Meeting in Toronto, Canada, from April 11-15, 2026. The company will feature its Hepatic Delivery System in three presentations, highlighting user experiences and preliminary clinical results related to percutaneous hepatic perfusion for liver metastases. This participation underscores Delcath's commitment to advancing treatment options for liver cancer.
Read more →Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
Delcath Systems announced the publication of the CHOPIN trial results in The Lancet Oncology, demonstrating the efficacy of combining percutaneous hepatic perfusion with immunotherapy for metastatic uveal melanoma. The trial showed a significant increase in progression-free and overall survival rates. Despite some safety concerns, the results highlight a promising treatment avenue for liver-dominant cancers.
Read more →Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
Delcath Systems reported strong financial results for Q4 and full year 2025, with total revenue reaching $20.7 million in Q4 and $85.2 million for the year. The company highlighted robust growth in procedure volume and positive operating cash flow, despite increased expenses. Looking ahead, Delcath anticipates continued momentum in 2026 driven by expanded treatment centers and positive clinical data.
Read more →